On Tuesday, Shares of Bank of America Corporation (NYSE:BAC), gained 1.19% to $17.88.
Bank of America Corporation has pledged to enhance the company’s current environmental business initiative from $50 billion to $125 billion in low-carbon business by 2025 through lending, investing, capital raising, advisory services and developing financing solutions for clients around the world.
The company initiative and commitment focus on energy efficiency, renewable energy and transportation, in addition to addressing other important areas like water conservation, land use and waste. This expanded second commitment builds on the company’s initial environmental business initiative established in 2007 and fulfilled in 2013, four years ahead of plan.
“We are putting our financial capital, our intellectual capital, and the strength of our partnerships to work to assist create a better future for all of us,” said Brian Moynihan, chief executive officer, Bank of America.
“We will continue to work with partners around the globe to develop innovative and scalable solutions that attract new investors and additional capital to clean energy and low-carbon infrastructure opportunities,” said Saggurti.
“Since making its original environmental business commitment in 2007, Bank of America has consistently been among the leaders in every branch of clean energy finance we track,” said Michael Liebreich, founder and chairman of the Advisory Board, Bloomberg New Energy Finance. “This new commitment means Bank of America is again setting the pace. To be considered a leading provider of financial services, in anything from energy to real estate, it’s crucial to be focused on funding low-carbon solutions, and Bank of America’s new commitment is a very noteworthy statement.”
Bank of America Corporation is a bank holding company. The company, through its auxiliaries, operates through Consumer and Business Banking; Consumer Real Estate Services; Global Wealth and Investment Administration; Global Banking; Global Markets; and Other segments.
Shares of Advanced Micro Devices, Inc. (NASDAQ:AMD), inclined 9.26% to $1.77, during its last trading session.
Advanced Micro Devices introduced the newest addition to its A-Series line of desktop processors. The A8-7670K APU provides a superb experience for Microsoft Windows 10, mainstream workloads, and eSports online gaming.
The A8-7670K is an affordable APU that combines the energy efficient processing power of an AMD CPU with the pixel pushing power of AMD Radeon™ graphics (GPU) in one convenient package. Users can easily multitask modern workloads and stream video in Windows® 10 or mow down their enemies in popular eSports online gaming titles such as Counter Strike®: Global Offensive. Powered by 10 compute cores (4 CPU + 6 GPU)1, the A8-7670K APU provides the processing and graphics capability budget conscious mainstream users need recently.
Advanced Micro Devices, Inc. operates as a semiconductor company worldwide. The company’s products primarily comprise x86 microprocessors as an accelerated processing unit (APU), chipsets, discrete graphics processing units (GPUs), and semi-custom System-on-Chip (SoC) products.
Finally, Inotek Pharmaceuticals Corporation (NASDAQ:ITEK), ended its last trade with 2.03% gain, and closed at $17.10.
Inotek Pharmaceuticals Corporation declared that Richard N. Spivey, PharmD, PhD, has been designated to its Board of Directors.
“I am happy to welcome Dr. Spivey to Inotek’s Board of Directors,” said David P. Southwell, President and Chief Executive Officer. “Rich brings a distinguished background in drug development and regulatory affairs spanning 30 years at leading pharmaceutical companies, counting most recently at Allergan as Senior Vice President of Global Regulatory Affairs. We will benefit from Rich’s expert guidance, especially on regulatory and commercial strategy.”
Dr. Spivey served as Senior Vice President of Global Regulatory Affairs at Allergan (AGN) during the approval and launch of Ozurdex, for the treatment of diabetic macular edema and Botox, a novel treatment for spasticity, chronic migraine, neurogenic bladder, overactive bladder and crow’s feet lines. In addition, he offered ongoing oversight for development programs in glaucoma and retinal disease, counting drug/device combination products. Before joining Allergan, Dr. Spivey headed the Research and Development function as Chief Scientific Officer of Meda AB following their acquisition of MedPointe Pharmaceuticals, where he was Chief Scientific Officer. Preceding to MedPointe, Dr. Spivey held positions at Pharmacia Corporation (now Pfizer, Inc.), Schering-Plough Corporation (now Merck & Co.), and Parke-Davis/Warner-Lambert (now Pfizer, Inc.)
“I believe that trabodenoson, as a novel adenosine mimetic, has the potential to become an important new therapy for ophthalmologists in their efforts to stop vision loss in patients with glaucoma,” said Dr. Spivey. “I am enthusiastic to join Inotek’s Board and assist support the team as we advance the development of trabodenoson monotherapy towards an NDA.”
Inotek Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for glaucoma.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
